This webinar series we will consider why particle size is important for pharmaceutical products and how answering this question can lead to the specification of a realistic method.
In this presentation we considered why a particle size specification may be required, reviewed the guidance provided in ICH Q6A and then considered how techniques such as laser diffraction and automated image analysis can aid formulation developers in material selection and in understanding the impact of formulation processing operations on likely product performance.
Learn how an appropriate method for particle size analysis can be developed based on an understanding of why particle size analysis is important.
This webinar series will consider the requirements for elemental analysis for pharmaceutical intermediates and final dosage forms and also how X-Ray Fluorescence (XRF) offers a simple, robust alternative to existing methods such as ICP-OES, ICP-MS and AAS.
In this presentation, we considered why elemental analysis is required, reviewed the guidance provided in ICH Q3D and then examined the guidance provided in USP +lt;735>and EP 2.2.37 for the use of XRF.
In this webinar we will consider how an appropriate method for XRF elemental analysis can be developed, including a live demonstration of the use of the technique.
This webinar series will consider the guidance available regarding polymorph and crystallinity analysis for pharmaceutical products and how appropriate methods can be developed using the technique of X-Ray Powder Diffraction (XRPD).
In this presentation we will discuss why a polymorph specification may be required, review the guidance provided in ICH Q6A and consider how XRPD can aid formulation developers in material selection and in understanding the impact of formulation processing operations on product performance.
We will consider how an appropriate method for XRPD analysis can be developed and how various sample preparation techniques can influence it.
We will focus on the advanced analysis methods available using an XRPD system which can help with understanding the distribution of components within pharmaceutical dosage forms and can also provide a means of describing amorphous materials.
